{
  "ticker": "EXEL",
  "company_name": "Exelixis, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04477512",
      "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Hormone Refractory Prostate Cancer",
      "start_date": "2021-02-19",
      "completion_date": "2025-09-10",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT04925284",
      "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors",
      "start_date": "2021-06-07",
      "completion_date": "2025-03-10",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT04412629",
      "title": "Cabozantinib in High Grade Neuroendocrine Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "High Grade Neuroendocrine Neoplasms",
      "start_date": "2020-11-24",
      "completion_date": "2026-09-30",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT03964337",
      "title": "Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic",
      "start_date": "2020-03-17",
      "completion_date": "2021-06-04",
      "enrollment": 0,
      "sponsor": "Duke University"
    },
    {
      "nct_id": "NCT03468218",
      "title": "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma",
      "start_date": "2018-09-18",
      "completion_date": "2026-10-29",
      "enrollment": 0,
      "sponsor": "Emory University"
    },
    {
      "nct_id": "NCT00451880",
      "title": "Study of XL281 in Adults With Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma",
      "start_date": "2007-02",
      "completion_date": "2011-10",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT07123103",
      "title": "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumors",
      "start_date": "2025-08-18",
      "completion_date": "2028-02",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT00796484",
      "title": "Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Cancer",
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT01441947",
      "title": "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Breast Cancer",
      "start_date": "2011-10",
      "completion_date": "2019-08-09",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT06132945",
      "title": "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Metastatic Renal Cell Carcinoma, Brain Metastases",
      "start_date": "2023-11-10",
      "completion_date": "2027-11",
      "enrollment": 0,
      "sponsor": "Memorial Sloan Kettering Cancer Center"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 19,
      "PHASE2": 22,
      "PHASE2, PHASE3": 1,
      "PHASE3": 5,
      "PHASE4": 1,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "COMPLETED": 13,
      "ACTIVE_NOT_RECRUITING": 11,
      "TERMINATED": 12,
      "RECRUITING": 12,
      "NOT_YET_RECRUITING": 2
    },
    "active_trials": 23,
    "completed_trials": 13,
    "conditions": [
      "Advanced Adult Hepatocellular Carcinoma",
      "Advanced Solid Cancers, Metastatic Cancer",
      "Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct",
      "Brain Metastases, Renal Cell Carcinoma",
      "Breast Cancer",
      "Cancer",
      "Cancer, Lymphoma",
      "Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma",
      "Castration-resistant Prostate Cancer, Metastatic Cancer",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
      "Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone",
      "Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer",
      "Colorectal Cancer",
      "Hepatocellular Carcinoma, Liver Cancer",
      "High Grade Neuroendocrine Neoplasms",
      "Kidney Cancer, Renal Cell Carcinoma",
      "Medullary Thyroid Cancer",
      "Merkel Cell Carcinoma, Skin Cancer",
      "Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma",
      "Metastatic Hormone Refractory Prostate Cancer",
      "Metastatic Prostate Cancer, Prostate Adenocarcinoma",
      "Metastatic Renal Cell Carcinoma, Brain Metastases",
      "Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor",
      "Metastatic Soft-tissue Sarcoma",
      "Metastatic Urothelial Carcinoma, Bladder Cancer",
      "Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential",
      "Neoadjuvant Treatment, Thyroid Cancer",
      "Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer",
      "Neuroblastoma, Sarcoma",
      "Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain",
      "Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors",
      "Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)",
      "Non-Small Cell Lung Cancer",
      "Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma",
      "Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)",
      "Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma",
      "Prostate Cancer",
      "Prostate Cancer Metastatic",
      "Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic",
      "Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia",
      "Renal Cell Carcinoma",
      "Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC)",
      "Solid Tumor",
      "Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor",
      "Solid Tumors",
      "Stomach Neoplasms, Esophageal Neoplasms",
      "Thyroid Cancer"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:19.542983",
    "search_query": "Exelixis, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Exelixis,+Inc."
  }
}